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Background: Questions remain regarding the use of the cephalosporins to treat infections caused by
extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. For example, should ceftazidime or cefepime
be used to treat infections with CTX-M ESBL-producing organisms with low MICs (minimum inhibitory
concentrations), according to the new Clinical and Laboratory Standards Institute’s (CLSI) recommendations for
susceptibility testing? Some studies have reported that in vitro MICs of cephalosporins increase as the inoculum
increases, which is the inoculum effect; however, most of the enzymes studied were SHV and TEM. In this study,
we aimed to investigate the inoculum effect on ceftazidime, cefepime and four other β–lactam agents against
CTX-M-ESBLs-producing Escherichia coli.
Methods: Antibiotic susceptibilities were determined using broth microdilution MIC methodology according to
the CLSI recommended with standard and 100-fold-higher inocula.
Results: An inoculum effect on meropenem and cefminox was not detected. The size of the inoculum affected
piperacillin/tazobactam activity against only 4 strains, all CTX-M-14 genotypes. The inoculum size affected the
activity of ceftazidime, cefepime and cefotaxime against 35%, 85%, 100% of strains, respectively. Among the strains
with an inoculum effect, CTX-M-14 was the most common ESBL genotype.
Conclusions: These findings suggest that meropenem is the most active compound against serious infections
caused by Escherichia coli producing ESBLs. Cefminox and piperacillin-tazobactam exhibit strong activity against
many strains. Until further studies are performed, clinicians should be aware that third- and fourth-generation
cephalosporins (such as ceftazidime and cefepime) are not reliable for serious infections even though in vitro tests
indicate susceptibility.
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The CLSI has revised susceptibility breakpoints for En-
terobacteriaceae and recommendations for testing for
ESBL production, and now recommends reporting the
MICs of cephalosporins, but not the production of ESBLs
[1]. Consequently, many ESBL-producing Escherichia coli
may be reported susceptible to ceftazidime or cefepime,
especially those producing CTX-M-ESBL, which are apt
to hydrolyze cefotaxime [2]. However, clinical correlations* Correspondence: chenbaiyi63@hotmail.com
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ESBL-producing organisms infections are lacking. More-
over, some in vitro studies show poor outcomes using cef-
tazidime or cefepime to treat the serious infections with
ESBL-producing organisms [3,4]. One reason for this dis-
parity is the inoculum effect, which means the MICs of
cephalosporins increase as the inoculum increase. Some
in vitro studies have shown an inoculum effect against
SHV- or TEM-ESBL-producing isolates [5,6]. It is un-
known whether the inoculum effect extends to the CTX-
M genotypes, the most widespread type of ESBLs in Asia,
especially in China [7,8]. Therefore, we aimed to investi-
gate the inoculum effect on ceftazidime, cefepime andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ESBL-producing Escherichia coli.Methods
Eighty non-replicate strains of Escherichia coli, identified
using the Vitek 2 system (bioMérieux S.A., Marcy I’Etoile,
France), were investigated in this study. The isolates were
selected from a collection of clinical isolates of patients
from the First Hospital of China Medical University. ESBL
production was confirmed phenotypically using double-
disc diffusion tests with ceftazidime with/without clavula-
nic acid and cefotaxime with/without clavulanic acid.
β-lactamases produced by isolates were characterized by
PCR gene sequencing, including CTX-M-14, CTX-M-15,
CTX-M-22, CTX-M-24 and CTX-M-79 (as reported by
our previous study [9]). Escherichia coli ATCC25922 was
used as the quality control strain for susceptibility testing.
This study was approved by the Ethics Committee of our
hospital (Approval number, 2013114) and conducted in
accordance with the ethical guidelines of the Declaration
of Helsinki.
MICs were determined by the broth microdilution
method in accordance with CLSI (2010) recommenda-
tions [1]. Susceptibility testing was performed using in-
oculum concentrations of approximately 1–5 × 105 CFU/
ml (the standard inoculum) and 1–5 × 107 CFU/ml (the
higher inoculum). Inoculum concentrations were esti-
mated by optical density measurement and verified by
quantitative subculture. An inoculum effect was defined
as an eightfold or greater increase in MIC when tested
with the high inoculum [5]. Comparision betweent CTX-
M-14-group and other-genotype-group were performed
by chi-square test using SPSS16.0. P value of < 0.05 were
considered statistically significant. Antimicrobial agents
meropenem, cefminox, piperacillin/tazobactam (tazobac-
tam 4 μg/ml), cefepime, ceftazidime and cefotaxime (ob-
tained from the National Institute for the Control of
Pharmaceutical and Biological Products) were tested.Table 1 The inoculum effects on six antimicrobial agents for
high-inoculum
Antimicrobial agent MIC (μg/ml) at standard and high inoculum
Standard inoculum High inocul
(1–5 × 105 CFU/ml inoculum) (1–5 × 107 C
Range MIC50 MIC90 Range
Meropenem ≤0.015 ~ 0.06 0.03 0.03 0.03 ~ 0.06
Cefminox 0.5 ~ 4 1 2 0.5 ~ 8
Piperacillin/tazobactam 4 ~ 32 8 32 8 ~ 256
Ceftazidime 1 ~ 32 4 16 8 ~ 128
Cefepime 4 ~ 32 8 32 32~ > 512
Cefotaxime 16 ~ 256 64 256 128~ > 512Results
The strains were isolated from blood (n = 40), urine (n =
25), ascites (n = 7), bile (n = 5) and pus (n = 3). The se-
quence analysis of lactamase-producing organisms de-
tected the ESBL genotypes CTX-M-14 (n = 44), CTX-M-
15 (n = 8), CTX-M-22 (n = 12), CTX-M-24 (n = 4) and
CTX-M-79 (n = 12). At the standard inoculum, the MICs
of cefotaxime were higher than the MICs of cefepime and
ceftazidime against all CTX-M strains (Table 1). The
MICs of meropenem and cefminox were very low and less
affected by the inoculum. An inoculum effect on piperacil-
lin/tazobactam was observed in only 4 strains, all geno-
type CTX-M-14. The MIC50 of ceftazidime was 4 μg/ml
at the low inoculum and 35% (28/80) of strains showed an
inoculum effect at the high inoculum (all 28 strains were
genotype CTX-M-14). An inoculum effect on cefepime
was observed for 85% (68/80) of isolates, the frequencies
of this inoculum effect, by genotype were CTX-M-14, 40/
44; CTX-M-15, 8/8; CTX-M-22, 12/12; CTX-M-24, 4/4;
and CTX-M-79, 4/12.Discussion
The production of ESBLs is the predominant cause of
resistance to β-lactam antibiotics in gram-negative bac-
teria. However, the antimicrobial substrate specificities
of different phenotypes of ESBLs vary. The common
phenotypes of the ESBL enzymes are TEM, SHV, CTX-
M and others. More recently, the CTX-M β-lactamases,
which have potent hydrolytic activity against cefotax-
ime, have been the most widespread β-lactamases in
Asia, especially in China. Therefore, we studied strains
containing CTX-M-encoded genes to explore their pre-
sumptive role as a cause of therapeutic failure. In this
study, the isolates contained CTX-M-14, CTX-M-22,
CTX-M-15, CTX-M-24 and CTX-M-79 encoding genes.
CTX-M-14 is the most common genotype in our area.
CTX-M-79 was first reported by Su Fei Tian et al. in
our previous study [9].80 strains of Escherichia coli at standard and






0.03 0.06 0 ≤0.015
2 4 0 2
8 64 4 2
32 64 28 0.25
512 >512 68 0.12
512 >512 80 0.12
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inoculum effect on cefotaxime susceptibility tests was
found to be most frequent; it was observed in 100% of
strains. The elevated cefotaxime MICs might be ex-
plained by the potent hydrolytic activity of CTX-M-
ESBLs against cefotaxime and could be the underlying
cause of therapeutic failure.
Based on the antimicrobial susceptibility data, most
CTX-M-14 strains were susceptible to ceftazidime at the
standard inoculum. However, at the high inoculum we
found the inoculum effect on ceftazidime was frequent,
MICs of 28 (35%) strains increased dramatically using
the high inoculum. Although the MICs of ceftazidime
were often low, ceftazidime might not be effective
against severe infections (such as abscesses, endocarditis,
meningitis, septic arthritis, osteomyelitis, and other
deep-seated infections with high concentrations of bac-
teria) due to the inoculum effect. All isolates with this
inoculum effect contained the CTX-M-14 encoding
gene, which is the most common type in our area. In
our area, we should scrutinize the use of ceftazidime to
treat such infections. Isolates containing the newly re-
ported genotype, CTX-M-79, did not show this inocu-
lum effect.
There is disagreement about the use of cefepime to
treat infections caused by ESBLs-producing organisms
when the in vitro testing indicates susceptibility. Cefe-
pime is reported to be less prone to hydrolysis by ESBLs
[10] than other cephalosporins. Notably, in animal
models of infections with such organisms, treatment
with cefepime has produced both successful and unsuc-
cessful therapeutic outcomes. In this study, at the stand-
ard inoculum, the MIC50 of cefepime was 8 μg/ml.
Using the high inoculum, MICs of most isolates (68/80)
increased more than eight-fold, showing an inoculum
effect. We examined the genotypes of strains with this
inoculum effect: as Table 2 shows, 40 strains had CTX-
M-14,and 28 strains belonged to other types (CTX-M-
15, 8; CTX-M-22, 12; CTX-M-24, 4; and CTX-M-79, 4).
Making comparision betweent CTX-M-14-group and
other-genotype-group by χ2 test, the two groups
displayed significant variousity (P = 0.001). Considering
the widespread prevalence of CTX-M-14-ESBL-produ-
cing organisms and this inoculum effect, cefepime may
be a less reliable agent for therapy of serious ESBLs
infection.Table 2 Analysis of strains with an inoculum effect on cefepim




CTX-M-14 producing strains 40a 16
Other genotypes 28 16
aP = 0.001 by chi-square test.Piperacillin-tazobactam was less subject to an inocu-
lum effect, it was only observed in four strains of CTX-
M-14 derived ESBLs. Piperacillin-tazobactam might have
better efficacy against pathogens that produce CTX-M
enzymes. A recent series analyzed the outcome of 43 ep-
isodes of Escherichia coli bacteremia caused by ESBL-
producing strains (primarily CTX-M-14). The mortality
rate of patients given a β-lactam/β-lactamase inhibitor
combination was lower than that of patients given either
a cephalosporin or fluoroquinolone [11]. However, in
the study of Lopez-Cerero et al., the inoculum effect of
piperacillin-tazobactam was more frequent than we ob-
served [12]. This difference may be due to differences in
ESBL genotypes, which were primarily TEM- and SHV-
ESBLs in Lopez-Cerero’s study, whereas our isolates
were all CTX-M ESBLs. It also may be related to MICs
differences among isolates from different regions. All
need further investigation.
At the standard-inoculum and the high inoculum, the
MICs of meropenem and cefminox were very low, with
no inoculum effect. The finding of meropenem is con-
sistent with previous reports of strains producing SHV-
and TEM-derived ESBLs [5,6]. It suggests that carbapen-
ems, such as meropenem, could be the best choice for
treating infections caused by ESBL producers. Although
we also detected no inoculum effect on cefminox, given
the limited data about the use of cefminox to treat
ESBL-producing organisms, further investigations are
warranted to evaluate its clinical efficacy.
Conclusions
In tests of CTX-M-ESBL-producing Escherichia coli iso-
lates, meropenem and cefminox were less influenced by
inoculum size. Piperacillin-tazobactam was subject to an
inoculum effect in the presence of certain ESBLs.
Inoculum effects were detected more frequently with
cefepime, ceftazidime and cefotaxime. These findings
suggest that meropenem could be the most active
compound against serious infections caused by Escheri-
chia coli producing ESBLs. Cefminox and piperacillin-
tazobactam exhibited strong activity against many of the
isolates. Until further studies are performed, clinicians
should be aware that third- and fourth-generation ceph-
alosporins (such as ceftazidime and cefepime) are not re-
liable for serious infections even though in vitro tests
indicate susceptibility.e
(μg/ml)
ard inoculum (5 × 105 CFU/ml) High inoculum (5 × 107 CFU/ml)
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